CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 100 target
Drug / intervention
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPRbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04016129
NCT04016129Phase 1RecruitingOn Track
CompareCT.gov

CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia

Shenzhen Geno-Immune Medical Institute·interventional·Posted Jul 11, 2019·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR for B-cell Leukemia. Currently recruiting, targeting 100 participants across 1 site.

Detailed Summary

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Leukemia
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20202021202220232024202520262027202820292030
First PostedJul 11, 2019
Enrollment StartJul 15, 2025
Primary CompletionJul 15, 2028
Study CompletionDec 15, 2029
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 7.0 years agoPrimary completion in 2.0 years

Arms & Interventions

4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPRexperimental

Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies

Biological: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR

Interventions

4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPRbiological

4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies